Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUCCINI real-world study of subcutaneous Duodopa in earlier advanced Parkinson's disease
NL-OMON58140Phase 4Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of levodopa in Parkinson's disease (PD), sponsored by AbbVie Inc. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON58140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58140.